Long-term in vitro study of paclitaxel-eluting bioresorbable core/shell fiber structures

Journal of Controlled Release

Volumn 126, Issue 2, 2008, Pages 139-148

  Kraitzer, Amir ^a   Ofek, Lia ^a   Schreiber, Reut ^a   Zilberman, Meital ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Controlled release; Degradation; Drug eluting fibers; Paclitaxel; Poly(dl lactic co glycolic acid)

Indexed keywords

BIODEGRADATION; COPOLYMERS; DRUG DELIVERY; EMULSIONS;

BIORESORBABLE CORE; COMPOSITE FIBERS; CONTROLLED RELEASE; FREEZE DRYING; POLYGLYCONATE CORE;

ONCOLOGY;

COPOLYMER; MAXON; ORGANIC COMPOUND; PACLITAXEL;

ARTICLE; BIODEGRADABLE IMPLANT; DRUG ELUTING STENT; DRUG RELEASE; EMULSION; FIBER; HYDROPHOBICITY; IN VITRO STUDY; KINETICS; PRIORITY JOURNAL;

CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; MATERIALS TESTING; PACLITAXEL; TIME;

EID: 38749111071     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2007.11.011     Document Type: Article

References (34)

1. Su S.H., Landau C.L., Chao R.Y., Timmons R.B., Meidell R.S., Tang L., and Eberhart R.C. Expandable bioresorbable endovascular stent with anti-platelet and anti-inflammation treatments. Circulation 104 II (2001) 500-507
2. Alikacem N., Yoshizawa T., Wilson C., and Nelson K.D. Quantitative MR Imaging study of intravitreal sustained release of VEGF in rabbits. Invest. Ophthalmol. Vis. Sci. 41 (2000) 1561-1569
3. Dunn R.L., Lewis D.H., and Goodson J.M. Monolithic fibers for controlled delivery of tetracycline. Proc. Int. Symp. Control. Rel. Bioact. Mater. 9 (1982) 157-163
4. Dunn R.L., English J.P., Stoner W.C., Potter A.G., and Perkins B.H. Biodegradable fibers for the controlled release of tetracycline in treatment of peridontal disease. Proc. Int. Symp. Control. Rel. Bioact. Mater. 14 (1987) 289-294
5. Dunn R.L., Lewis D.H., and Beck L.R. Fibrous polymer for the delivery of contraceptive steroids to the female reproductive track. In: Lewis D.H. (Ed). Controlled Release of Pesticides and Pharmaceuticals (1981), Plenum Press, New York 125-146
6. Eenink M.D.J., Feijen J., Oligslanger J., Albers J.H.M., Rieke J.C., and Greidonus P.J. Biodegradable hollow fibers for the controlled release of hormones. J. Control. Rel. 6 (1987) 225-237
7. Polacco G., Cascone M.G., Lazzeri L., Ferrara S., and Giusti P. Biodegradable hollow fibers containing drug-loaded nanoparticles as controlled release systems. Polym. Int. 51 12 (2002) 1464-1472
8. Lazzeri L., Cascone M.G., Quiriconi S., Morabito L., and Giusti P. Biodegradable hollow microfibers to produce bioactive scaffolds. Polym. Int. 54 (2005) 101-107
9. Kraitzer A., and Zilberman M. Paclitaxel-loaded composite fibers: microstructure and emulsion stability. J. Biomed. Mater. Res. A. 81 2 (2007) 427-436
10. Babapulle M.N., and Eisenberg M.J. Coated stents for prevention of restenosis: part I. Circulation 106 (2002) 2734-2740
11. Duda S.H., Poerner T.C., Wiesinger B., Rundback J.H., Tepe G., Wiskirchen J., and Haase K.K. Drug-eluting stents: potential applications for peripheral occlusive disease. J. Vasc. Interv. Radiol. 14 (2003) 291-301
12. Lewis A.L., Tolhurst L.A., and Stratford P.W. Analysis of a phosphorylcholine-based polymer coating on a coronary stent pre- and post-implantation. Biomaterials 23 (2002) 1697-1706
13. Woods T.C., and Marks A.R. Drug-eluting stents. Ann. Rev. Med. 55 (2004) 169-178
14. Tamai H., Igaki K., Kyo E., Kosuga K., Kawashima A., Matsui S., Komori H., Tsuji T., Motohara S., and Uehata H. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation 102 (2000) 399-404
15. Tamai H., Igaki K., Tsuji T., Kyo E., Kosuga K., Kawashima A., Matsui S., Komori H., Motohara S., Uehata H., and Takeuchi E. A biodegradable poly-l-lactic acid coronary stent in porcine coronary artery. J. Interv. Cardiol. 12 (1999) 443-449
16. Zilberman M., Schwade N.D., and Eberhart R.C. Protein-loaded bioresorbable fibers and expandable stents: mechanical properties and protein release. J. Biomed. Mater. Res. B. 69 (2004) 1-10
17. Zilberman M., and Eberhart R.C. Drug-eluting bioresorbable stents for various applications. Ann. Rev. Biomed. Eng. 8 (2006) 153-180
18. Dhanikula A.B., and Panchagnula R. Localized paclitaxel delivery. Int. J. Pharm. 183 2 (2000) 85-100
19. Silber S., and Grube E. The Boston scientific antiproliferative paclitaxel eluting stent (TAXUS). In: Serruys P.W. (Ed). Handbook of Coronary Stents (2001), Martin Dunitz, London 311-319
20. AHFS Drug Information. American Society of Health System Pharmacists (1989), Bethseda 1075-1086
21. Rowinsky E.K., and Donehower R.C. Drug therapy: paclitaxel (Taxol). N. Engl. J. Med. 332 (1995) 1002-1014
22. Yamawaki T., Shimokawa H., Kozai T., Miyata K., Higo T., Tanaka E., Egashira K., Shiraishi T., Tamai H., and Igaki K. Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. J. Am. Coll. Cardiol. 32 (1998) 780-786
23. Drachman D.E., Edelman E.R., Seifert P., Groothuis A.R., Bornstein D.A., Kamath K.R., Palasis M., Yang D., Nott S.H., and Rogers C. Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J. Am. Coll. Cardiol. 36 (2000) 2325-2332
24. Suh H., Jeong B., Rathi R., and Kim S.W. Regulation of smooth muscle cell proliferation using paclitaxel-loaded poly(ethylene oxide)-poly(lactide/glycolide) nanospheres. J. Biomed. Mater. Res. 42 (1998) 331-338
25. Alexis F., Venkatraman S.S., Rath S.K., and Boey F. In vitro study of release mechanisms of paclitaxel and rapamycin from drug-incorporated biodegradable stent matrices. J. Cont. Rel. 98 (2004) 67-74
26. Grube E., Silber S., Hauptmann K.E., Mueller R., Buellesfeld L., Gerckens U., and Russel M.E. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 107 (2003) 38-42
27. Tanabe K., Serruys P.W., Degertekin M., Guagliumi G., Grube E., Chan C., Munzel T., Belardi J., Ruzyllo W., Bilodeau L., Kelbaek H., Ormiston J., Dawkins K., Roy L., Strauss B.H., Disco C., Koglin J., Russell M.E., and Colombo A. Chronic arterial responses to polymer-controlled paclitaxel-eluting stents: comparison with bare metal stents by serial intravascular ultrasound analysis: data from the randomized TAXUS-II trial. Circulation 109 (2004) 196-200
28. Tanabe K., Serruys P.W., Grube E., Smits P.C., Selbach G., van der Giessen W.J., Staberock M., de Feyter P., Müller R., Regar E., Degertekin M., Ligthart J.M.R., Disco C., Backx B., and Russell M.E. TAXUS III trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in slow-release polymer formulation. Circulation 107 (2003) 559-564
29. Stone G.W., Ellis S.G., Cox D.A., Hermiller J., O'Shaughnessy C., Mann J.T., Turco M., Caputo R., Bergin P., Greenberg J., Popma J.J., and Russell M.E. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N. Engl. J. Med. 350 (2004) 221-231
30. Tsuji T., Tamai H., Igaki K., Kyo E., Kosuga K., Hata T., Nakamura T., Fujita S., Takeda S., Motohara S., and Uehata H. Biodegradable stents as a platform to drug loading. Int. J. Cardiovasc, Interv. 5 (2003) 13-16
31. Mu L., and Feng S.S. A novel controlled release formulation for the anticancer drug Paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. J. Cont. Rel. 86 (2003) 33-48
32. Richard T.L., and Burt H.L. Paclitaxel loaded poly (l-lactic acid) (PLLA) microspheres II. The effect of processing parameters on microsphere morphology and drug release kinetics. Int. J. Pharm. 281 (2004) 103-106
33. Chitkara D., Shikanov A., Kumar N., and Domb A.J. Biodegradable injectable in situ depot-forming drug delivery systems. Macromol. Biosci. 6 (2006) 977-990
34. Shikanov A., Vaisman B., Krasko M.Y., Nyska A., and Domb A.J. Poly(sebatic acid-co-ricinoleic acid) biodegradable carrier for paclitaxel: in-vitro release and in-vivo toxicity. J. Biomed. Mater. Res. A. 69 1 (2004) 47-54